吡哌酸锌对实验烧伤愈合的影响

目的观察吡哌酸锌软膏促进烧伤愈合的作用。方法用230℃的圆铁板造成大鼠背部烧伤,以不同浓度的吡哌酸锌及磺胺嘧啶银霜、磺胺嘧啶锌软膏、吡哌酸软膏、软膏基质每日涂药一次,连续15d。d16测量未愈合烧伤创面面积。结果吡哌酸锌软膏及磺胺嘧啶锌软膏均能明显促进创面愈合,两者之间无显著差异（P＞0．05）,但磺胺嘧啶银霜、吡哌酸软膏等促进创面愈合作用不明显（P＞0．05）。结论吡哌酸锌软膏能明显促进烧伤创面的愈合。     

丹参的体外抑菌作用研究

目的：探讨丹参的体外抑菌作用。方法：用K-B纸片扩散法。100％丹参浸出液滤纸片对大肠杆菌、金黄色葡萄球菌、白色葡萄球菌、变形杆菌、乙型链球菌抑菌作用进行了研究。结果：丹参对以上细菌均有抑菌作用。结论：丹参在体外有明显的抑菌作用。     

肝细胞癌化疗栓塞后经皮瘤内注射无水乙醇的疗效

目的比较肝动脉化疗栓塞术(THAE)后经皮瘤内注射无水乙醇(PEI)与单纯THAE治疗单个肝细胞癌的疗效。方法53例肝细胞癌随机分成A(26例)、B(27例)两组。A组单纯THAE治疗;B组THAE治疗后,在CT引导下行PEI治疗。结果THAE组肿瘤治疗的部分缓解率为26.7%,1、2、3年生存率分别为56.0%、30.0%、0.0%。THAE+PEI组肿瘤治疗的部分缓解率为55.5%(P<0.05),1、2、3年生存率分别为91.0%、57.0%、22.0%(P<0.05)。结论THAE+PEI较单纯THAE对单个肝细胞癌的治疗更安全有效。     

超滤法提取肌苷工艺

采用超过滤膜对肌苷发酵液进行超滤，再经浓缩、结晶、干燥，得到粗苷。实验确定最佳超滤条件为：压力0．15Mpa，温度64．9℃。肌苷提取收率为85．7％，其粗苷中肌苷含量为73．2％。比离子交换法提取肌苷，收率提高15个百分点。     

流感DNA疫苗免疫BALB/c小鼠克服母源性抗体干扰的研究

目的 为了克服母源性抗体对子代的免疫抑制作用,寻找避免母源性抗体干扰的流感疫苗免疫策略.方法 以小鼠为动物模型,接种流感灭活疫苗或DNA疫苗,并用致死量流感病毒感染.感染后检测小鼠的存活率、肺部病毒滴度、体内抗体滴度等指标,对疫苗的保护效果进行评价.结果 母代与子代免疫相同的疫苗,不论是灭活疫苗还是DNA疫苗,子代体内的母源性抗体都抑制了子代免疫后的自动免疫应答,表现为子鼠接种疫苗后不能抵御致死量流感病毒感染;母代免疫流感灭活疫苗,子代免疫神经氨酸酶DNA疫苗,子鼠能够克服母源性抗体干扰,抵御致死量流感病毒感染;母代和子代免疫不同的DNA疫苗,即母代免疫血凝素或神经氨酸酶DNA疫苗,子代免疫神经氨酸酶或血凝素DNA疫苗,也能达到克服母源性抗体干扰的目的 .结论 流感DNA疫苗免疫BALB/c小鼠能克服母源性抗体的干扰,这为临床新生儿抗母源性抗体干扰的研究提供了实验参考.     

降酶保肝合剂对四氯化碳致大鼠急性肝损伤的防治作用

目的：观察降酶保肝合剂对CCl4皮下注射致大鼠急性肝损伤的防治作用。方法：采用大鼠皮下注射CCl4造成大鼠急性肝损伤模型并于造模前、后灌胃给药。结果：该剂能改善CCl4致急性肝损伤模型大鼠血清ALT、AST和SOD、MDA、GSH指标；对肝细胞病变有一定程度的保护作用。结论：降酶保肝合剂抗肝损伤的作用与其降酶、清除活性氧自由基、抗脂质过氧化反应有关。     

丹酚酸B及欧芹素乙对溶血磷脂酰胆碱刺激牛主动脉平滑肌细胞增殖的影响

目的　研究溶血磷脂酰胆碱 (L PC)对牛主动脉平滑肌细胞 (BASMC)增殖的影响及丹酚酸 B和欧芹素乙的抑制作用。方法　体外培养 BASMC,用 MTT法测定细胞增殖。结果　 L PC在 2 .5× 10 - 9～ 2 .5× 10 - 6 g/ L 剂量依赖性地促进 BASMC增殖 ;丹酚酸 B(1× 10 - 9～ 1× 10 - 6 mol/ L)和欧芹素乙 (1× 10 - 7～ 1× 10 - 3m ol/ L)浓度依赖性地抑制 L PC的作用。结论　 L PC可促进 BASMC增殖 ,丹酚酸 B和欧芹素乙可抑制 L PC的作用     

新辅助化疗在晚期鼻咽癌治疗中的应用价值

目的 :探讨新辅助化疗在治疗中晚期鼻咽癌 (nasopharyngealcarcinoma ,NPC)中的应用价值。方法 :经病理检查确诊的 80例中晚期 (Ⅱ～Ⅳ期 )初治NPC患者 ,于放疗前随机分成两组 ,即新辅助化疗 +放射治疗组 (化放组 )和单纯放疗组(单放组 )各 4 0例 ,观察新辅助化疗对肿瘤患者的缓解率和毒副反应 ,对比放射治疗后两组的疗效。结果 :化放组的全身性毒副反应发生率、复发率及转移率均较低 ,而肿瘤控制率及生存率明显高于单放组 ;化疗组与单放组的 5年生存率分别为 6 5 %和 4 2 5 % ,两组间相比较均有显著性差异 (P值均 <0 0 5 )。结论 :对中晚期NPC宜先进行新辅助化疗 ,再行放射治疗 ,可以提高疗效     

Comparing sulindac with indomethacin for closure of ductus arteriosus in preterm infants

Objectives: A prospective study comparing the efficiacy and side-effects of oral sulindac with intravenous indomethacin in clinically stable preterm infants (<1750 g) requiring non-invasive closure of haemodynamically significant patent ductus arteriosus.
Methodology: As maturity and birthweight are the two major determinants of ductal closure, infants were matched as closely as possible for these parameters. An eligible patient was first assigned to the sulindac group and a subsequent patient with similar gestational age (± 1 week) and birthweight (±100 g) to the previously recruited infant would automatically receive indomethacin. A total of eight infants were enrolled in each group.
Results: The ductus arteriosus was successfully closed in all eight infants receiving indomethacin, and in seven of eight infants receiving sulindac. No significant differences were found with regards to the ductal size between the two groups at diagnosis or on each of the consecutive days of treatment ( P >0.25). More renal adverse effects were encountered in the indomethacin group. Significant differences in changes from baseline value for urine output, plasma sodium, urea and creatinine concentrations were noted at 24, 48 and 72 h after commencement of treatment between the two groups ( P <0.05). All the parameters returned to normal or pre-treatment levels 48 h after stopping therapy. Unexpectedly, severe gastrointestinal complications were encountered in the sulindac group.
Conclusions: Sulindac is capable of promoting ductal constriction in clinically stable preterm infants without compromising the renal function. The spectrum of gastrointestinal complications observed in sulindac treated infants were similar to those described for indomethacin. The use of sulindac for ductal closure in the preterm infant should remain experimental.     

Aberrant crypt focus promotion and glucose intolerance: correlation in the rat across diets differing in fat, n-3 fatty acids and energy

McKeown-Eyssen (Cancer Epidemiol. Biomarkers Prevent., 3, 687-695, 1994) and Giovannucci (Cancer Causes Control, 6, 164-179, 1995), noting the striking similarity in lifestyle risk factors for colorectal cancer and insulin resistance, proposed that the hyperinsulinemia, glycemia and hypertriglyceridemia associated with insulin resistance promotes colon cancer. To compare the effect of diet on colon cancer promotion and insulin resistance in the F344 rat, we assessed the effect of fat, n-3 fatty acids and energy in pairwise comparisons on average size of aberrant crypt foci (ACF) and on glucose intolerance in the same animals in a single experiment. Diets high in fat and energy increased and diets with increased n-3 fatty acids and calorie restriction decreased both ACF growth and glucose intolerance compared with control diets. The measures of promotion of colon cancer and insulin resistance were strongly correlated (n = 98, r = 0.67, P < 0.001). In addition, both were highly correlated with daily energy intake (r = 0.62 and 0.66) and were also correlated with basal (post-prandial) insulin, glucose and triglycerides (r = 0.31-0.53, P < 0.01). We concluded that ACF growth and glucose intolerance are correlated for a wide range of diets and that increased circulating energy (glucose and triglycerides) may lead to both colon cancer promotion and insulin resistance.